行情

ARNA

ARNA

阿里纳制药
NASDAQ

实时行情|Nasdaq Last Sale

44.48
-2.31
-4.94%
交易中 15:20 02/27 EST
开盘
45.77
昨收
46.79
最高
46.44
最低
42.46
成交量
67.49万
成交额
--
52周最高
64.48
52周最低
42.46
市值
22.29亿
市盈率(TTM)
4.122
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ARNA价格均价为67.64,最高价位83.00,最低价为51.00。

EPS

ARNA 新闻

更多
  • Top Marijuana Stocks on the NASDAQ for March 2020
  • Investopedia · 2小时前
  • Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
  • Zacks · 4小时前
  • Edited Transcript of ARNA earnings conference call or presentation 26-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 6小时前
  • Cantor Fitzgerald Reiterates Overweight on Arena Pharmaceuticals, Lowers Price Target to $56
  • Benzinga · 8小时前

所属板块

生物技术和医学研究
-2.27%
制药与医学研究
-1.73%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

ARNA 简况

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
展开

微牛提供Arena Pharmaceuticals, Inc.(NASDAQ-ARNA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ARNA股票新闻,以帮助您做出投资决策。